J ohnson and others, 1 in their response to our recent paper, 2 highlight the need for transparency with respect to economic evaluations within rare diseases. We agree and wish to stress our belief that the same concern must be attached to reimbursement decisions with respect to such diseases. To demonstrate our commitment to such transparency, we would like to take this opportunity to respond to the specific concerns raised by Johnson and others.
Johnson and others. It is unclear how, in a disease for which patients are routinely followed up in specialist clinics, such a high degree of study attrition was found. Hillmen and others state that ''a 36-month cut-off was used for safety and efficacy assessments to ensure that there were a sufficient number.'' Given the dropout of 86.7% of patients by 36 months, we question whether this data can truly be seen as a measure of efficacy.
As explained in correspondence with Dr. Johnson, given the complexity of our model we used the DEALE method to estimate the underlying mortality rate. 6 This method will overestimate mortality in early years and underestimate it in later years, thus favoring treatments that may have an effect on survival. 7 Within our model, the survival rate at 3 years with eculizumab was estimated to be 93% (not the 89% assumed by Johnson and others), slightly lower than the 97.6% in the Hillmen paper. Despite the limitations of the Hillmen paper addressed above, we can adapt the mortality rates to reproduce the 97% rate at 3 years. This analysis leads to an incremental cost-utility ratio (ICUR) for eculizumab of $2.2 million compared with the original estimate of $2.1 million. Thus, concerns over this aspect of the model can be alleviated. 3 In terms of validation of our model, we compare the outputs of our model to studies that include long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria (PNH) prior to the introduction of eculizumab. In a long-term observational cohort study by Hillmen and others 3 of 80 PNH patients, mortality at 25 years was 72%, whereas in our model the figure for standard of care ranged from 68% to 80% dependent on transfusion requirements. 8 Another larger, long-term study by Socié and others 9 of 220 PNH patients found survival at 10 years of 65%-our model suggests a range of 61%-68%. We believe this provides strong evidence of the external validity of the model.
Johnson and others question one of the parameter estimates in our model: the relative rate of thrombosis from taking warfarin as a primary prophylaxis versus not taking warfarin. 10 They are correct that this value was not obtained from a PNH population. Indeed, in our paper we stated that given the paucity of data in rare diseases, in certain instances data from a wider patient population were used. An analysis assuming no decrease in thrombosis with warfarin would lead to an ICUR for eculizumab of $2.1 million, whereas an analysis assuming that warfarin would lead to no thromboses produces an ICUR of $2.2 million.
Johnson and others question the relevance of opportunity costs as a factor to be considered with respect to reimbursement of drugs for rare disease. We do not, as suggested by Johnson and others, believe that this an open issue. When considering any further health care expenditure it is necessary to consider the value of any benefits foregone by adopting one intervention over another. Any expenditure, no matter the magnitude, that is inefficient would necessarily result in displaced health benefits: that is, society as a whole being worse off with respect to the accumulated health benefits. Within our report, we list a number of health care interventions that could be considered cost-effective but are not funded in Canada and that could be provided with the same amount of resources required for a positive reimbursement decision for eculizumab. 2 The evidence to support a further argument proposed by Johnson and others, that eculizumab is a life-saving treatment and should be subject to a higher threshold value for incremental costeffectiveness ratios, is weak. Although in the UK, the National Institute for Health and Care Excellence (NICE; formerly the National Institute for Clinical Excellence) advocates a premium for end-of-life therapies that extend life, the suggested premium would not be sufficient to make eculizumab cost-effective and, furthermore, the rationales for such premiums have been questioned. 11, 12 Eculizumab may be a life-extending treatment but it is not an end-of-life treatment, as the mean undiscounted survival for standard of care in our model was 11.6 years. Thus, in this regard, eculizumab is not dissimilar to many treatments of common chronic conditions. The evidence from studies that have directly assessed the incremental value to be placed on rarity, above and beyond all other criteria, suggests little public appetite for discriminating in favor of patients with rare diseases over those with common diseases, thus suggesting no basis for increasing the cost-effectiveness threshold. [13] [14] [15] Our report stands as a careful exposition on how transparent economic evaluations can and should be conducted in the context of rare diseases. Such evaluations are both feasible and essential to ensure the optimal use of scarce health care resources. We used a wide evidence base to populate the model and, where necessary, made assumptions that are at worst neutral toward the product under consideration. To demonstrate our commitment to transparency, we extend to others the same invitation we offered to Dr. Johnson-we would be happy to consider conducting any further meaningful sensitivity analysis suggested to us.
